SOURCES SOUGHT
A -- Atopic Dermatitis and Vaccinia Network: Clinical Studies Consortium
- Notice Date
- 3/13/2003
- Notice Type
- Sources Sought
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Institutes of Allergy and Infectious Diseases, Contract Management Branch 6700 B Rockledge Room 2230 MSC7612, Bethesda, MD, 20892-7605
- ZIP Code
- 20892-7605
- Solicitation Number
- RFP-NIH-NIAID-DAIT-04-06
- Archive Date
- 4/5/2003
- Point of Contact
- Barry Johnson, Contract Specialist, Phone 301-402-8409, Fax 301-480-5253, - Lawrence Butler, Contracting Officer, Phone 301-496-0192, Fax 301-402-0972,
- E-Mail Address
-
BJohnson@niaid.nih.gov, lb13t@nih.gov
- Description
- THIS IS NOT A REQUEST FOR PROPOSALS AND DOES NOT COMMIT THE GOVERNMENT TO AWARD A CONTRACT NOW OR IN THE FUTURE. NO SOLICITATION IS AVAILABLE AT THIS TIME. BASED ON RESPONSES RECEIVED FROM THIS SOURCES SOUGHT, THIS ACQUISITION MAY BE SOLICITED AS A 100% SMALL BUSINESS SET-ASIDE, NAICS CODE 541710, WITH A SIZE STANDARD OF 500 EMPLOYEES. The Division of Allergy, Immunology and Transplantation (DAIT) of the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), DHHS is conducting a market survey to determine the availability and capability of small business firms with the expertise to establish and implement a Clinical Studies Consortium. One award is anticipated. The Clinical Studies Consortium will be one of three components of an Atopic Dermatitis and Vaccinia Immunization Network that will be created via contract awards in mid fiscal year 2004. The Network will have three components: a Clinical Studies Consortium, an Animal Studies Consortium, and a Statistical and Data Coordinating Center. Each component will be established under separate contracts. Subcontracting will be encouraged. The purpose of the Clinical Studies Consortium is to develop and implement a plan to eliminate the risk for eczema vaccinatum in atopic dermatitis (AD) patients who are immunized with vaccinia. The Consortium will perform clinical studies on AD patients to evaluate innate and adaptive immune responses. These studies should provide important information about immune abnormalities that account for susceptibility to eczema vaccinatum, and should facilitate future design of safer and more effective vaccines for AD patients. The tasks that the Clinical Studies Consortium must fulfill will be coordinated with the Animal Studies Consortium and the Statistical and Data Coordinating Center. In their capability statement, organizations capable of fulfilling this effort, at a minimum, must demonstrate capabilities to: 1) Establish a Clinical Studies Consortium consisting of institutions capable of providing the clinical, scientific, technical and administrative expertise necessary to perform clinical studies in patients with AD; 2) Manage an organizational plan that must include processes for: a) establishing research priorities; b) reviewing, modifying, approving and disapproving research studies; c) allocating resources; d) monitoring and evaluating progress and performance; e) redirecting scientific focus and reallocating resources; and f) establishing and maintaining effective working relationships with pharmaceutical and biotechnology industries and with other NIAID-supported programs on biodefense and relevant non-biodefense research; 3) Propose a governance plan for the Network Executive Committee and chair and participate in this committee, which will be the governing body of the Network for all three components; 4) Design and implement safe protocols that assess immune function and gene expression in atopic dermatitis patients, both in vivo and in vitro, in response to: a) a defined set of antigens; and b) immunization with selected attenuated viruses; 5) Obtain and store blood and tissue samples from atopic dermatitis patients; 6) Identify atopic dermatitis patients with documented disseminated vaccinia and/or disseminated herpes simplex and/or severe molluscum contagiosum infection, for recruitment in a Registry; 7) Provide appropriate resources critical to clinical, scientific, technical and administrative support in a cost-effective manner. 8) Ensure an orderly transition of contract-related activities and materials to a successor Contractor or the Government at contract completion. Interested parties must submit a written capability statement, inclusive of references, that identifies the organization's ability to perform the efforts described above. Capability statements must identify the business status of the organization (i.e. non-profit, small business, 8(a), or other corporate or noncorporate entity). It is anticipated that the period of performance for the contracts will be five (5) years. Interested small business organizations that believe they possess the capabilities necessary to undertake this project should submit two (2) copies of their capability statement addressing the areas above, to be received no later than 3:30 PM local time on March 21, 2003, to the attention of Barry Johnson at the address listed above. See Government-wide Numbered Note 22. NO COLLECT CALLS WILL BE ACCEPTED. FACSIMILE AND E-MAIL TRANSMISSIONS WILL BE ACCEPTED. Point of Contact Barry Johnson, Contract Specialist, Phone 301-451-3694, Fax 301-402-0192, Email bj109t@nih.gov; Lawrence M. Butler, Senior Contracting Officer, Phone 301-496-0192, Fax 301-402-0972, Email lb13t@nih.gov
- Record
- SN00278641-W 20030315/030313213419 (fbodaily.com)
- Source
-
FedBizOpps.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |